Search Results

With the rise of immunotherapies, it is critical to ensure patient safety, as the toxicity profiles of immunotherapy agents are vastly different from traditional cytotoxic chemotherapies.

In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.

As more patients are treated with single and combination immunotherapies for cancer, early identification and management of immune-related adverse events (irAEs) is critical to achieving desired outcomes with these new drugs. ACCCBuzz recently talked with Matthew R. Zibelman, MD, for perspective on irAE management in patients treated with immune checkpoint inhibitor therapy. Dr. Zibelman is a genitourinary …